Commercial Credit Report for Societe Adwya SA

CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals. Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue. We also offer solutions that can help ease private company financial risk assessment. Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively.

A partial report preview for Societe Adwya SA is shown below. Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database. To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

	Societe Adwya SA
Route de la Marsa Km 14 B.P 658
Phone: +216 71854888p:+216 71854888	LA MARSA, 2070 Tunisia	Fax: +216 71854900f:+216 71854900

This company is no longer actively traded on any major stock exchange.

Business Summary

Ste Adwya SA is a Tunisia-based company engaged in the provision of generic and licensed pharmaceuticals for human and veterinary use. The Company’s range of products spans several medical areas, including cardiology, dermatology, neuro-psychiatry, metabolism and nutrition, diabetes and urology, among others. It offers drugs traded under the brand name: Novadol, Anxiomyl, Celiprol, Enapril, Glimid, Mesatec, Spirazol and Celopram, among others; drugs manufactured under license agreements with GlaxoSmithkline, Solvay, Sanofi-Aventis, Abbot, and Astra Zeneca, among others, and drugs prepared for third party laboratories. The Company operates two production sites: Alpha, which manufactures the non-penicillin products, and Beta, which specializes in the production of antibiotics. The new branch of activity launched by the Company is the natural therapy range, API-AR and multivitamins range, Advita multivitamins. In February 2014, it established a subsidiary Adwya Promotion Cote d'Ivoire.

Scores and Ratings

FRISK^® Score	Z'' Score	PAYCE^® Score	DBT Index	Moody's Rating	Fitch Rating	DBRS Rating
-	Yes	-	Yes	-	-	-

Financials, News and Filings

Latest Statement	Last Audit	News	SEC Filings	Bankruptcy Filings	Suit & Judgment Filings	Tax Lien Filings
6/30/2022	12/31/2021	Yes	-	-	-	-

Industries

SIC Code	Description
2834	Pharmaceutical preparations

Officers and Directors

Title	Name	Title Date	Start Date
Chairman of the Board	TaharEL MATERI	1/1/2005	1/1/2005
Chief Executive Officer	Mohamed A.Zehani	1/26/2011
Deputy Chief Executive Officer	BeyaEl Materi Annabi
12 additional Officers and Directors records available in full report.

Business Names

Business Name
ADWYA
Societe Adwya SA

General Information

Number of Employees:	487	(As of 6/30/2022)
Outstanding Shares:	21,528,000	(As of 6/30/2022)
Stock Exchange:	TUN
Fax Number:	+216 71854900

SITE MAP | ABOUT US | DIRECTORY | STOCK QUOTE: CRMZ | SIGN IN